Anika Therapeutics, Inc. 8-K

What Happened
Anika Therapeutics, Inc. announced on July 10, 2026 that it entered into a Fifth Amendment to its existing credit agreement with Bank of America, N.A. The amended agreement provides a $50.0 million senior revolving line of credit (with lender/admin roles held by Bank of America) that matures on July 10, 2031, and allows Anika, subject to conditions and lender approval, to request up to an additional $50.0 million for a potential $100.0 million aggregate commitment.

Key Details

• Revolver amount: $50.0 million initial revolving credit; option to increase by up to $50.0 million (max $100.0M) subject to lender approval.
• Maturity: July 10, 2031.
• Interest: Loans priced at SOFR + spread ranging from 0.25% to 1.25%, determined by Anika’s consolidated leverage ratio at borrowing.
• Fees / costs: Commitment fee on unused amounts of 0.20%–0.30% per annum (paid quarterly); loan origination costs amortized over the five-year term.
• Covenants & security: The agreement contains customary reps, warranties, affirmative/negative covenants and financial covenants limiting leverage and requiring minimum interest coverage; lenders hold a first-priority lien on substantially all assets (with certain intangible asset exceptions).
• Filing context: Reported under Item 1.01 (material definitive agreement) and Item 2.03 (creation of a direct financial obligation); the Fifth Amendment is filed as Exhibit 10.1.

Why It Matters
This amendment secures multi-year liquidity for Anika through a committed revolving credit line, supporting working capital and flexibility for operations or transactions. The pricing (SOFR + spread) ties borrowing cost to the company’s leverage, and the financial covenants and first-priority lien are important constraints investors should note because they affect balance sheet flexibility and priorities in case of default.